These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
9. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. Agabiti Rosei E; Salvetti M High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901 [TBL] [Abstract][Full Text] [Related]
11. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
12. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation. Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934 [TBL] [Abstract][Full Text] [Related]
13. Rosmarinic acid inhibits nicotine-induced C-reactive protein generation by inhibiting NLRP3 inflammasome activation in smooth muscle cells. Yao Y; Mao J; Xu S; Zhao L; Long L; Chen L; Li D; Lu S J Cell Physiol; 2019 Feb; 234(2):1758-1767. PubMed ID: 30146678 [TBL] [Abstract][Full Text] [Related]
14. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. Gebauer K; Reinecke H Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075 [TBL] [Abstract][Full Text] [Related]
16. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum A; Fisman EZ; Motro M; Adler Y Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960 [TBL] [Abstract][Full Text] [Related]
17. Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials. Xie S; Galimberti F; Olmastroni E; Luscher TF; Carugo S; Catapano AL; Casula M; Cardiovasc Res; 2024 Mar; 120(4):333-344. PubMed ID: 38373008 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N; J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514 [TBL] [Abstract][Full Text] [Related]
19. Real-world use of PCSK9 inhibitors: A single-center experience. Sarsam S; Berry A; Degheim G; Singh R; Zughaib M J Int Med Res; 2019 Jan; 47(1):265-270. PubMed ID: 30280628 [TBL] [Abstract][Full Text] [Related]
20. Determinants of Achieved LDL Cholesterol and "Non-HDL" Cholesterol in the Management of Dyslipidemias. Packard CJ Curr Cardiol Rep; 2018 Jun; 20(8):60. PubMed ID: 29904807 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]